Del Potter
Dr. Del Potter specializing in psychiatric anthropology, ethno psychopharmacology, and neuropharmacology, and organic chemistry. He received clinical training at the San Francisco Psychoanalytic Institute. His early research focused on the cross-cultural psychohistory of shamanic practitioners, indigenous psychotherapeutic practice and the phytochemistry of shamanic formulation in Mexico, Ecuador, Brazil and Colombia. He worked with Alexander Shulgin on novel chemistry of DMT and 5-MeO-DMT related compounds, and worked as Chief Science Officer for Alvarius Pharmaceuticals on first in man studies of 5-MeO-DMT for substance abuse disorders. He currently consults for Pangea Bontanica which is using metabolomic analysis to develop pharmaceutical products from botanicals worldwide. He founded Spiritus Bioscience last year to focus on contouring the psychedelic experience with final formulation and delivery technology.
The Next Generation of Pharmaceutical Psychedelics
This presentation will discuss the importance of pharmaceutical formulation strategies for psychedelic drug delivery in clinical applications, new developments in the field, and how those strategies differ from and complement the development of novel psychedelic compounds. Opportunities for delivery innovation in Measure 109 service centers will be discussed. Approaches to formulation will also be placed in the context of the strategies employed by non-Western, indigenous shamanic practitioners.